Teva Pharmaceutical Industries Ltd. won a court ruling tossing a $235 million verdict over its copy of GlaxoSmithKline Plc’s Coreg heart drug.
Teva’s generic version didn’t infringe a Glaxo patent, U.S. District Judge Leonard P. Stark ruled March 28.
Glaxo’s patent is for the use of the compound carvedilol to lessen the chance of death from congestive heart failure. The company claimed Teva infringed the patent, even when it was only selling its version of Coreg for hypertension.
The judge said that there wasn’t enough proof Teva caused doctors to prescribe the generic for congestive heart failure. Instead, there was ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.